Game-Changing ADHD Treatment: Akili's EndeavorRx Shows Significant Improvement in Adult Attention Functioning

Akili Inc AKLI announced the topline results of the STARS-ADHD-Adult trial evaluating EndeavorRx (AKL-T01) in adults with attention deficit/hyperactivity disorder (ADHD)

The trial demonstrated statistically significant improvement in attention functioning after six weeks of treatment, achieving its predefined primary efficacy outcome.

Significant improvements were also seen across a range of secondary and exploratory outcomes. 

EndeavorRx treatment was well-tolerated, with minimal side effects and no serious device-related adverse events reported.

EndeavorRx is the first-and-only FDA-authorized treatment delivered through a video game experience for inattention in children ages 8-12 with ADHD.

In January, Akili announced topline data from a pivotal study of EndeavorRx in adolescents with ADHD ages 13-17. 

Nearly 72.5% of adults reported at least some improvement in their quality of life, and nearly 45.8% met a prespecified threshold for clinically meaningful improvement.

Overall, 11 of the participants in the trial (5%) reported a treatment-emergent adverse device event, most commonly nausea (1.8%) and headache (1.4%). There were no serious adverse device events.

Additional study information and results:

83% of patients demonstrated a clinical response to the treatment.

Over one-third (36.6%) of adults with ADHD moved into the non-clinical or normative range.

Price Action: AKLI shares are up 33.90% at $1.46 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!